Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftaroline fosamil and NXL104 vs Doripenem in cUTI
NCT01281462Phase 2Completed
- Sponsor
- Forest Laboratories
- Start
- Dec 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of avibactam and ceftaroline fosamil in complicated urinary tract infection (cUTI) (3 arms), sponsored by Forest Laboratories. Primary endpoints: Microbiological response of Microbiologically Evaluable (ME) at Test of Cure (TOC) and Evaluate safety up to 42 days. Started Dec 2010; status: completed.
02
Drugs
avibactamceftaroline fosamil
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT01281462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281462.